This Week's Top Industry News

BUSY WEEK? Here are the *TOP INDUSTRY NEWS* stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum.*

1. **Pfizer Settles Medicaid Claims for Wyeth Subsidiary for $785 Million**

   Pfizer's Wyeth subsidiary has reached an agreement in principle to resolve claims regarding Wyeth's practices relating to the calculation of Medicaid rebates for its drug, Protonix (pantoprazole sodium), between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009. Under the agreement, Wyeth will make a payment of $784.6 million to resolve these claims. **Read More**

2. **Biocon Gets European OK for Generic of AstraZeneca's Crestor**

   Biocon Ltd., a biopharmaceutical company, based in Bengaluru, India, has received European approvals for various dosage forms of rosuvastatin calcium, a generic equivalent of AstraZeneca's anticholesterol drug, Crestor, which posted 2015 global sales of $5 billion. **Read More**

3. **UK Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit**

   Eli Lilly lost a round in patent litigation regarding Alimta (pemetrexed disodium), a chemotherapy drug, and one of its top-selling drugs with 2015 global sales of $2.5 billion. The UK High Court decided that the Alimta vitamin regimen patent would not presently be infringed by Actavis marketing pemetrexed trometamol in the UK, France, Italy, and Spain with instructions to dilute the product only with dextrose solution. **Read More**

4. **Merck & Co Plans to Hire 200 Staff to Support Irish Manufacturing Facilities**

   MSD, the name for Merck & Co. outside of the US and Canada, will create 200 new jobs across three of its Irish manufacturing sites respectively in Carlow, Cork, and Tipperary by the end of 2016. The new roles span operations, quality, engineering, supply chain, and commercial operations. **Read More**

5. **Cipla Closes on Two US Generics Acquisitions**

   Cipla has closed on its previously announced acquisitions of two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc., for a combined $550 million. The acquisitions provide Cipla scale in the US generics market and its first manufacturing base in the US. **Read More**

6. **Novo Nordisk Investing in New Hampshire Manufacturing Plant**

   Novo Nordisk is proceeding with a multi-million dollar investment in its 170,000-square foot manufacturing facility in West Lebanon, New Hampshire. The company acquired the facility in 2014. **Read More**

7. **Athenex Plans $1.62 Billion, 10-Year Investment in Manufacturing and Drug Discovery**

   Athenex, a pharmaceutical company focused on oncology, plans to invest $1.62 billion in drug discovery and advanced manufacturing in New York State in Dunkirk and Buffalo over the next 10

years, which includes a new high-potency manufacturing facility. **Read More**

8. **Astellas Completes $379 Million Tender Offer for Ocata Therapeutics**

   Astellas Pharma has completed its tender for Ocata Therapeutics, a biotechnology company focused on regenerative medicines, primarily cell therapies, for approximately $379 million. Astellas had announced that it was acquiring Ocata in November 2015. **Read More**

9. **AstraZeneca, Eli Lilly, University of Michigan Partner**

   AstraZeneca and its global biologics R&D arm, MedImmune, have entered into a collaboration with the University of Michigan and Eli Lilly and Company to identify new therapeutic targets for treating chronic kidney diseases. **Read More**

10. **Recipharm To Invest $45 Million for Serialization Capabilities**

    Recipharm, a CDMO based in Jordbro, Sweden, plans to invest EUR 40 million ($44.6 million) over the next three years to provide solutions for the serialization processes. The investment is in line with the European Union's (EU) Falsified Medicines Directive Safety Features Delegated Regulation, which requires that serialization of licensed drug products will be a legal requirement for companies in the EU from early 2019. **Read More**

Preview of DCAT Week '16 Education Program

To Insource or Outsource Drug Product Development and Manufacturing? That is the Question

What is the optimal approach for pharmaceutical development and manufacturing? An upcoming DCAT Week '16 education program provides first-hand insight from Bristol-Myers Squibb and Pfizer on how they are approaching partnerships with raw material suppliers, CDMOs, and CMOs. **Read More**

The DCAT organization is happy to provide this service to its members each Friday. Have a great weekend!

About *Top Industry News*

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.

DCAT
DRUG, CHEMICAL & ASSOCIATED TECHNOLOGIES
A S S O C I A T I O N

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.

One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org